Published in Mol Pathol on February 01, 2000
Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol (2005) 3.16
Epstein-Barr virus infection in ex vivo tonsil epithelial cell cultures of asymptomatic carriers. J Virol (2004) 1.48
Compartmentalization and transmission of multiple epstein-barr virus strains in asymptomatic carriers. J Virol (2003) 1.45
The switch from latent to productive infection in epstein-barr virus-infected B cells is associated with sensitization to NK cell killing. J Virol (2006) 1.35
Plasma cell-specific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter. J Virol (2007) 1.31
Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol Pathol (2000) 1.26
Epstein-Barr virus infection and human malignancies. Int J Exp Pathol (2001) 1.24
The Epstein-Barr virus BcRF1 gene product is a TBP-like protein with an essential role in late gene expression. J Virol (2012) 1.05
Epstein-Barr virus infection of Langerhans cell precursors as a mechanism of oral epithelial entry, persistence, and reactivation. J Virol (2007) 0.98
Identification of Epstein-Barr virus strain variants in hairy leukoplakia and peripheral blood by use of a heteroduplex tracking assay. J Virol (2002) 0.97
Activation of Kaposi's sarcoma-associated herpesvirus lytic gene expression during epithelial differentiation. J Virol (2005) 0.97
Epstein-Barr virus latent genes. Exp Mol Med (2015) 0.96
Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity. Microbes Infect (2010) 0.94
DNA methylation in gastric cancer, related to Helicobacter pylori and Epstein-Barr virus. World J Gastroenterol (2014) 0.91
An Epstein-Barr virus encoded inhibitor of Colony Stimulating Factor-1 signaling is an important determinant for acute and persistent EBV infection. PLoS Pathog (2012) 0.88
Methylation-mediated gene silencing as biomarkers of gastric cancer: a review. World J Gastroenterol (2014) 0.88
Cancer stem-like cell: a novel target for nasopharyngeal carcinoma therapy. Stem Cell Res Ther (2014) 0.88
Identification of B cells as a major site for cyprinid herpesvirus 3 latency. J Virol (2014) 0.86
Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders. Clin Dev Immunol (2012) 0.84
Themed issue: the biology and pathology of the Epstein-Barr virus. Mol Pathol (2000) 0.83
Secreted Oral Epithelial Cell Membrane Vesicles Induce Epstein-Barr Virus Reactivation in Latently Infected B Cells. J Virol (2016) 0.82
EBV Persistence-Introducing the Virus. Curr Top Microbiol Immunol (2015) 0.82
Telomerase activity impacts on Epstein-Barr virus infection of AGS cells. PLoS One (2015) 0.78
The infectious kiss: newly infected B cells deliver Epstein-Barr virus to epithelial cells. Proc Natl Acad Sci U S A (2006) 0.78
The nuclear and adherent junction complex component protein ubinuclein negatively regulates the productive cycle of Epstein-Barr virus in epithelial cells. J Virol (2010) 0.78
Visual detection and evaluation of latent and lytic gene expression during Epstein-Barr virus infection using one-step reverse transcription loop-mediated isothermal amplification. Int J Mol Sci (2013) 0.75
Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med (1985) 4.78
Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med (1984) 4.47
Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol (1992) 2.83
Epstein-Barr virus persistence and virus-associated tumours. Lancet (1994) 2.60
Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci U S A (1988) 2.12
Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer (1989) 1.97
Epstein-Barr virus small nuclear RNAs are not expressed in permissively infected cells in AIDS-associated leukoplakia. Proc Natl Acad Sci U S A (1990) 1.90
The switch between latency and replication of Epstein-Barr virus. J Infect Dis (1990) 1.89
Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol (1997) 1.72
Epstein-Barr virus infection in oral hairy leukoplakia: virus replication in the absence of a detectable latent phase. J Gen Virol (1991) 1.70
Epstein-Barr virus and the B cell: that's all it takes. Trends Microbiol (1996) 1.62
Replication of EBV in epithelial cells during infectious mononucleosis. Nature (1977) 1.61
Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood (1992) 1.51
Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin Cancer Biol (1996) 1.27
Role of epithelium in EBV persistence and pathogenesis of B-cell tumours. Lancet (1988) 1.25
Strict lymphotropism of Epstein-Barr virus during acute infectious mononucleosis in nonimmunocompromised individuals. Blood (1997) 1.23
Epstein-Barr virus latent and replicative gene expression in oral hairy leukoplakia. Histopathology (1992) 1.04
The Epstein-Barr virus:host balance in acute infectious mononucleosis patients receiving acyclovir anti-viral therapy. Int J Cancer (1989) 1.04
Epstein-Barr virus gene expression and epithelial cell differentiation in oral hairy leukoplakia. Am J Pathol (1991) 0.95
Clinical syndromes associated with EB virus infection. Adv Intern Med (1972) 0.84
Applications of in situ hybridization. Int Rev Exp Pathol (1991) 0.79
Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet (2001) 7.31
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med (1998) 5.33
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet (1991) 4.76
Mycobacterial infections in AIDS patients, with an emphasis on the Mycobacterium avium complex. Rev Infect Dis (1987) 4.54
Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J Immunol (1988) 4.47
Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy. Ann Intern Med (1978) 4.15
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol (1994) 4.08
Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med (1996) 3.94
Simple method for elimination of aminoglycosides from serum to permit bioassay of other antimicrobial agents. Antimicrob Agents Chemother (1977) 3.91
Aspergillosis complicating neoplastic disease. Am J Med (1973) 3.80
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol (1992) 3.41
Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J Gen Virol (1987) 3.28
Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis (1972) 3.28
Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob Agents Chemother (1987) 3.06
Hemagglutination typing of Escherichia coli: definition of seven hemagglutination types. J Clin Microbiol (1980) 3.03
Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol (1999) 2.88
Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus. Antimicrob Agents Chemother (1973) 2.85
Hemolysin and K antigens in relation to serotype and hemagglutination type of Escherichia coli isolated from extraintestinal infections. J Clin Microbiol (1981) 2.82
In vitro studies of piperacilin, a new semisynthetic penicillin. Antimicrob Agents Chemother (1978) 2.82
Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (1990) 2.72
Epstein-Barr virus infection and replication in a human epithelial cell system. Nature (1992) 2.62
Epstein-Barr virus persistence and virus-associated tumours. Lancet (1994) 2.60
Tobramycin (nebramycin factor 6): in vitro activity against Pseudomonas aeruginosa. Appl Microbiol (1971) 2.60
Pneumococcal immunisation and the healthy elderly. Lancet (1992) 2.58
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med (1993) 2.56
Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis (1986) 2.56
Nontuberculous mycobacterial infections: a clinical review. Infection (2004) 2.56
Septicemia due to Aeromonas hydrophila: clinical and immunologic aspects. J Infect Dis (1973) 2.55
Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest (1979) 2.50
Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group. Ann Intern Med (1990) 2.45
Comparison of methods for assessing in vitro antibiotic synergism against Pseudomonas and Serratia. J Lab Clin Med (1975) 2.41
Radioimmunoassay, acetylating radio-enzymatic assay, and microbioassay of gentamicin: a comparative study. J Lab Clin Med (1975) 2.30
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol (1989) 2.23
Nocardia asteroides infection complicating neoplastic disease. Am J Med (1971) 2.23
Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli. Antimicrob Agents Chemother (1980) 2.23
Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene (1998) 2.22
Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med (1991) 2.20
A short 5' flanking region containing conserved sequences is required for silkworm alanine tRNA gene activity. Proc Natl Acad Sci U S A (1983) 2.19
Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity (1997) 2.18
Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem (1999) 2.17
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis (1997) 2.14
Piperacillin therapy for serious bacterial infections. Am J Med (1980) 2.14
A simultaneous outbreak of meningococcal and influenza infections. N Engl J Med (1972) 2.11
Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med (1980) 2.11
Interaction of Mycobacterium avium complex with human macrophages: roles of membrane receptors and serum proteins. Infect Immun (1991) 1.97
Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer (2002) 1.95
Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol (1989) 1.92
Gram-negative rod bacteremia: microbiologic, immunologic, and therapeutic considerations. Ann Intern Med (1977) 1.90
Antimicrobial synergism in the therapy of gram-negative rod bacteremia. Chemotherapy (1978) 1.88
Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol (1993) 1.88
Epstein-Barr virus receptors on human pharyngeal epithelia. Lancet (1986) 1.88
Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail. Am J Med (1977) 1.86
CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene (1996) 1.85
LMP1 structure and signal transduction. Semin Cancer Biol (2001) 1.85
Functional role of antibody against "core" glycolipid of Enterobacteriaceae. J Clin Invest (1975) 1.80
Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol (1999) 1.76
Infectious complications of neoplastic disease. Med Clin North Am (1971) 1.75
Infectious complications of human bone marrow transplantation. Medicine (Baltimore) (1979) 1.74
Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene (1997) 1.74
Therapeutic and epidemiologic recommendations to reduce the spread of type-I beta-lactamase resistance. Diagn Microbiol Infect Dis (1992) 1.74
Human epithelial cell expression of an Epstein-Barr virus receptor. J Gen Virol (1987) 1.73
Pseudomonas aeruginosa vaccine in cancer patients. Ann Intern Med (1973) 1.73
The role of exotoxins in the pathogenesis of Pseudomonas aeruginosa infections. J Infect Dis (1980) 1.73
Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol (1997) 1.72
Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides. J Infect Dis (1972) 1.71
Epstein-Barr virus infection in oral hairy leukoplakia: virus replication in the absence of a detectable latent phase. J Gen Virol (1991) 1.70
Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria. Am J Med (1987) 1.69
Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med (1992) 1.68
Quantitative granulocyte chemiluminescence in the rapid detection of impaired opsonization of Escherichia coli. Infect Immun (1977) 1.66
Improved acetylating radioenzymatic assay of amikacin, tobramycin, and sisomicin in serum. Antimicrob Agents Chemother (1975) 1.63
Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia. Am J Med (1976) 1.62
Recombinant granulocyte-macrophage colony-stimulating factor activates human macrophages to inhibit growth or kill Mycobacterium avium complex. J Leukoc Biol (1990) 1.62
A large region controls tRNA gene transcription. J Mol Biol (1985) 1.61
A new treatment for patients with short-bowel syndrome. Growth hormone, glutamine, and a modified diet. Ann Surg (1995) 1.61
In vitro studies with netilmicin compared with amikacin, gentamicin, and tobramycin. Antimicrob Agents Chemother (1977) 1.60
HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol (1993) 1.58
Activation of the small GTPase Cdc42 by the inflammatory cytokines TNF(alpha) and IL-1, and by the Epstein-Barr virus transforming protein LMP1. J Cell Sci (1999) 1.57
Nosocomial infections in the immunocompromised adult. Am J Med (1981) 1.56
Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis (1992) 1.56
An animal model of Mycobacterium avium complex disseminated infection after colonization of the intestinal tract. J Infect Dis (1992) 1.56
Trimethoprim-sulfamethoxazole in the treatment of adults with pneumonia due to Pneumocystis carinii. Rev Infect Dis (1982) 1.55
Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex. Antimicrob Agents Chemother (1988) 1.54
Restricted complement activation by Escherichia coli with the K-1 capsular serotype: a possible role in pathogenicity. J Immunol (1978) 1.54
Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology (1992) 1.53
Moxalactam therapy for bacterial infections. Arch Intern Med (1981) 1.53
Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice. Antimicrob Agents Chemother (1989) 1.52
Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood (1992) 1.51
P53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J Pathol (1993) 1.51
Intracellular killing of Mycobacterium avium complex by rifapentine and liposome-encapsulated amikacin. J Infect Dis (1987) 1.49
Non-Hodgkin's lymphoma, coeliac disease, and Epstein-Barr virus: a study of 13 cases of enteropathy-associated T- and B-cell lymphoma. J Pathol (1995) 1.49
In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents. Antimicrob Agents Chemother (1985) 1.49
The properties of a new polymerase III transcription factor reveal that transcription complexes can assemble by more than one pathway. EMBO J (1987) 1.49